Investor Information

Investor Information

Volpara Health Technologies (ASX: VHT) is a digital health company focused on early detection of breast cancer by improving the quality of screening using artificial intelligence (AI).

VHT was founded in 2009 by four of the world’s leading breast imaging experts: Professor Sir John Michael Brady and Dr Ralph Highnam from the University of Oxford, Professor Nico Karssemeijer from the University of Nijmegen and Professor Martin Yaffe from the University of Toronto. VHT headquarters (R&D and engineering) were established by Dr Highnam in Wellington, New Zealand.

The first Australian users of Volpara products include Dr Jones & Partners Medical Imaging (Adelaide, SA), Flinders Medical Centre (Adelaide, SA), Lyell McEwan Hospital (Elizabeth Vale, SA), MIA Monash Radiology (Melbourne, VIC), Imaging Associates - Mitcham Private Hospital (Melbourne, VIC), Imaging Associates Radiology (Wagga Wagga, NSW), Sydney Breast Clinic (NSW), Women’s & Breast Imaging (Perth) and Wesley Breast Clinic (Auchenflower, QLD). Volpara users in Auckland, New Zealand are the breast imaging pioneers Auckland Breast Centre and St Marks Breast Centre.

VHT Investor Newsletters

Sign up for our VHT investor newsletters here.

April 2018

February 2018

December 2017

October 2017

August 2017

 

Contact Us

Investor Relations email

investors@volparasolutions.com

Main business address

Level 7, 44 Victoria Street, Wellington Central,
Wellington, 6011, New Zealand

Registered offices

Volpara Health Technologies
Level 7, 44 Victoria Street, Wellington Central,
Wellington, 6011, New Zealand

JFDCPA Advisers
Suite #9, Level 1, 357 Military Road
Mosman, NSW 2088, Australia